{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T01:17:47Z","timestamp":1793063867405,"version":"4.5.0"},"reference-count":22,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>The recent rejection of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy by the U.S. Food and Drug Administration (FDA) is a dramatic moment in the re-emergence of psychedelic research. In this perspective, I argue that it represents a case study for paradigmatic tensions within psychopharmacology. The regulatory system is still influenced by a paradigm that sees the therapeutic effects of drugs as primarily biological, and context is noise to control for. An emergent paradigm considers the therapeutic effects of drugs as interactive with context. Psychedelics are the anomaly that questions the dominant paradigm, mainly due to the determination of psychedelic researchers that the medicines are drugs with psychotherapy. While some of the critique offered by the FDA towards MAPS\/Lykos\u2019s studies is crucial, much of it is related to the experiential and psychotherapeutic elements \u2013 which the FDA claims not to regulate. This leads to some paradoxes within the regulatory procedure, which hint at a need for a shift in how psychedelic-assisted therapy is regulated and researched. Both regulators and researchers will need to find ways to accommodate each other in service of a successful integration of a new paradigm in which drugs and psychotherapy interact.<\/jats:p>","DOI":"10.1177\/02698811241309611","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T23:25:08Z","timestamp":1735255508000},"page":"313-315","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":13,"title":["A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9990-6029","authenticated-orcid":false,"given":"Leor","family":"Roseman","sequence":"first","affiliation":[{"name":"Department of Psychology, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1159\/000346144"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2010.08.011"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118754710"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293349"},{"key":"e_1_3_2_6_1","unstructured":"FDA (2023) Psychedelic drugs: Considerations for clinical investigations. Guidance for industry. Available at: https:\/\/www.fda.gov\/media\/169694\/download (accessed 1 July 2024)."},{"key":"e_1_3_2_7_1","unstructured":"FDA-Advisory-Committee (2024) June 4 2024 Meeting of the Psychopharmacologic Drugs Advisory Committee-Final Meeting Roster. Available at: https:\/\/www.fda.gov\/media\/179059\/download (accessed 1 July 2024)."},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.623985"},{"key":"e_1_3_2_9_1","volume-title":"The Structure of Scientific Revolutions","author":"Kuhn TS","year":"1962","unstructured":"Kuhn TS (1962\/1997) The Structure of Scientific Revolutions. Chicago, IL: University of Chicago Press."},{"key":"e_1_3_2_10_1","article-title":"Impact of active placebo controls on estimated drug effects in randomised trials: A systematic review of trials with both active placebo and standard placebo","volume":"3","author":"Laursen DR","year":"2023","unstructured":"Laursen DR, Nejstgaard CH, Bj\u00f8rkedal E, et al. (2023) Impact of active placebo controls on estimated drug effects in randomised trials: A systematic review of trials with both active placebo and standard placebo. Cochrane Database Syst Rev 3: MR000055.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0300501"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.13370"},{"key":"e_1_3_2_13_1","article-title":"Active placebos versus antidepressants for depression","author":"Moncrieff J","year":"1996","unstructured":"Moncrieff J, Wessely S, Hardy R, et al. (1996) Active placebos versus antidepressants for depression. Cochrane Database Syst Rev 2004: CD003012.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.788155"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jhmas\/jrs050"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.857372"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1177\/02698811231182602"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.22181"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-55688-4_3"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230664"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00733"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.01.073"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/20008066.2023.2297536"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811241309611","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811241309611","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811241309611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:12:01Z","timestamp":1777507921000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811241309611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/02698811241309611"],"URL":"https:\/\/doi.org\/10.1177\/02698811241309611","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]}}}